社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
junior_daddy
IP属地：未知
+关注
帖子 · 215
帖子 · 215
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
junior_daddy
junior_daddy
·
2021-11-16
Pls like
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars<blockquote>纳斯达克指数早盘下跌，特斯拉市值跌破1万亿美元</blockquote>
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.
Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars<blockquote>纳斯达克指数早盘下跌，特斯拉市值跌破1万亿美元</blockquote>
看
2,792
回复
1
点赞
3
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-10
Pls like
非常抱歉，此主贴已删除
看
3,417
回复
1
点赞
5
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-09
Pls like
非常抱歉，此主贴已删除
看
3,187
回复
2
点赞
3
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Pls like
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>
看
3,191
回复
5
点赞
10
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Pls like
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>
看
3,053
回复
1
点赞
9
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-08
Tell me your opinion about this news...
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>
Regeneron shares rose 2.2% in premarket trading. Regeneron Pharmaceuticals Inc said on Monday a sing
Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>
看
2,341
回复
评论
点赞
8
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-06
Pls like and comment
非常抱歉，此主贴已删除
看
2,957
回复
1
点赞
5
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-04
Pls like 👍
5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>
These were some of the fastest-growing large-cap stocks on the planet over a three-year stretch.
5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>
看
3,955
回复
评论
点赞
7
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-03
Pls like
非常抱歉，此主贴已删除
看
3,280
回复
评论
点赞
1
编组 21备份 2
分享
举报
junior_daddy
junior_daddy
·
2021-11-02
Pls like
Cathie Wood Stands to Make a Lot of Money From Skillz Stock<blockquote>凯西·伍德(Cathie Wood)将从Skillz股票中赚很多钱</blockquote>
SKLZ stock, while volatile, has the potential to be a 10-bagger
Cathie Wood Stands to Make a Lot of Money From Skillz Stock<blockquote>凯西·伍德(Cathie Wood)将从Skillz股票中赚很多钱</blockquote>
看
3,716
回复
评论
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3574927270640767","uuid":"3574927270640767","gmtCreate":1611834519815,"gmtModify":1625538661889,"name":"junior_daddy","pinyin":"juniordaddyjuniordaddy","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":62,"headSize":415,"tweetSize":215,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.18%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.03%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":12,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":871032924,"gmtCreate":1636992768969,"gmtModify":1636992769258,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/871032924","repostId":"1105194762","repostType":4,"repost":{"id":"1105194762","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636990511,"share":"https://www.laohu8.com/m/news/1105194762?lang=zh_CN&edition=full","pubTime":"2021-11-15 23:35","market":"us","language":"en","title":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars<blockquote>纳斯达克指数早盘下跌，特斯拉市值跌破1万亿美元</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105194762","media":"Tiger Newspress","summary":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.","content":"<p>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p><p><blockquote>纳斯达克指数在早盘交易中转跌，特斯拉市值跌破1万亿美元。根据SEC披露的文件，马斯克12日出售了120万股特斯拉股票。至此，自11月8日以来，马斯克已出售约634万股特斯拉股票。马斯克承诺出售10%的特斯拉股票，也就是1705万股，所以马斯克只卖出了承诺的37.1%，还需要卖出至少1070万股特斯拉股票。此外，Musk暗示将出售更多特斯拉股票；“大空头”Michael Burry发推称，马斯克只想高位套现。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars<blockquote>纳斯达克指数早盘下跌，特斯拉市值跌破1万亿美元</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars<blockquote>纳斯达克指数早盘下跌，特斯拉市值跌破1万亿美元</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-15 23:35</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.<img src=\"https://static.tigerbbs.com/201cf466934fa60cc63374e64a0db551\" tg-width=\"772\" tg-height=\"563\" width=\"100%\" height=\"auto\"><img src=\"https://static.tigerbbs.com/c5d7f306762ab2851bfef58a237e2d55\" tg-width=\"772\" tg-height=\"560\" referrerpolicy=\"no-referrer\">According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.</p><p><blockquote>纳斯达克指数在早盘交易中转跌，特斯拉市值跌破1万亿美元。根据SEC披露的文件，马斯克12日出售了120万股特斯拉股票。至此，自11月8日以来，马斯克已出售约634万股特斯拉股票。马斯克承诺出售10%的特斯拉股票，也就是1705万股，所以马斯克只卖出了承诺的37.1%，还需要卖出至少1070万股特斯拉股票。此外，Musk暗示将出售更多特斯拉股票；“大空头”Michael Burry发推称，马斯克只想高位套现。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉",".IXIC":"NASDAQ Composite"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105194762","content_text":"Nasdaq Index turned down in morning trading with Tesla's market value fell below 1 trillion dollars.According to the documents disclosed by the SEC, Musk sold 1.2 million Tesla Motors shares on the 12th. So far, Musk has sold about 6.34 million Tesla Motors shares since November 8. Musk promised to sell 10% of Tesla Motors shares, that is, 17.05 million shares, so Musk has sold only 37.1% of his promise, and needs to sell at least 10.7 million shares of Tesla Motors shares. In addition, Musk hinted that he would sell more Tesla Motors shares; Michael Burry, a \"big bear\", tweeted that Musk only wanted to cash out at a high position.","news_type":1,"symbols_score_info":{"TSLA":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":2792,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847946892,"gmtCreate":1636475732215,"gmtModify":1636475733291,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/847946892","repostId":"1127189501","repostType":4,"isVote":1,"tweetType":1,"viewCount":3417,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844264318,"gmtCreate":1636432279510,"gmtModify":1636432280528,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844264318","repostId":"1121670869","repostType":4,"isVote":1,"tweetType":1,"viewCount":3187,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034736,"gmtCreate":1636376382655,"gmtModify":1636376383707,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":5,"repostSize":0,"link":"https://laohu8.com/post/844034736","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://www.laohu8.com/m/news/1141245956?lang=zh_CN&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨 2.2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量其抗体鸡尾酒可将感染 COVID-19 的风险降低 81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩说，结果表明，抗体疗法REGEN-COV有可能提供对新冠肺炎感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法之前在给药后的第一个月内显示风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron 表示，在 8 个月的评估期内，REGEN-COV 组中没有因 COVID-19 住院的病例，但安慰剂组中记录了 6 起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构在7月份扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中接触感染者的高风险人群的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国被授权用于治疗轻度至中度新冠肺炎疾病患者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-08 20:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨 2.2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量其抗体鸡尾酒可将感染 COVID-19 的风险降低 81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩说，结果表明，抗体疗法REGEN-COV有可能提供对新冠肺炎感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法之前在给药后的第一个月内显示风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron 表示，在 8 个月的评估期内，REGEN-COV 组中没有因 COVID-19 住院的病例，但安慰剂组中记录了 6 起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构在7月份扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中接触感染者的高风险人群的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国被授权用于治疗轻度至中度新冠肺炎疾病患者。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":3191,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034413,"gmtCreate":1636376371509,"gmtModify":1636376372559,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":9,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/844034413","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://www.laohu8.com/m/news/1141245956?lang=zh_CN&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨 2.2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量其抗体鸡尾酒可将感染 COVID-19 的风险降低 81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩说，结果表明，抗体疗法REGEN-COV有可能提供对新冠肺炎感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法之前在给药后的第一个月内显示风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron 表示，在 8 个月的评估期内，REGEN-COV 组中没有因 COVID-19 住院的病例，但安慰剂组中记录了 6 起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构在7月份扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中接触感染者的高风险人群的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国被授权用于治疗轻度至中度新冠肺炎疾病患者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-08 20:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨 2.2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量其抗体鸡尾酒可将感染 COVID-19 的风险降低 81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩说，结果表明，抗体疗法REGEN-COV有可能提供对新冠肺炎感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法之前在给药后的第一个月内显示风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron 表示，在 8 个月的评估期内，REGEN-COV 组中没有因 COVID-19 住院的病例，但安慰剂组中记录了 6 起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构在7月份扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中接触感染者的高风险人群的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国被授权用于治疗轻度至中度新冠肺炎疾病患者。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":3053,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":844034236,"gmtCreate":1636376360851,"gmtModify":1636376361825,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Tell me your opinion about this news...","listText":"Tell me your opinion about this news...","text":"Tell me your opinion about this news...","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/844034236","repostId":"1141245956","repostType":4,"repost":{"id":"1141245956","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1636375961,"share":"https://www.laohu8.com/m/news/1141245956?lang=zh_CN&edition=full","pubTime":"2021-11-08 20:52","market":"us","language":"en","title":"Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1141245956","media":"Tiger Newspress","summary":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a sing","content":"<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨 2.2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量其抗体鸡尾酒可将感染 COVID-19 的风险降低 81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩说，结果表明，抗体疗法REGEN-COV有可能提供对新冠肺炎感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法之前在给药后的第一个月内显示风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron 表示，在 8 个月的评估期内，REGEN-COV 组中没有因 COVID-19 住院的病例，但安慰剂组中记录了 6 起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构在7月份扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中接触感染者的高风险人群的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国被授权用于治疗轻度至中度新冠肺炎疾病患者。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron shares rose 2.2% in premarket trading<blockquote>再生元股价在盘前交易中上涨 2.2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-08 20:52</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Regeneron shares rose 2.2% in premarket trading.</p><p><blockquote>再生元股价在盘前交易中上涨 2.2%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1d06980fde1a0bd99affdab9ee4beb4b\" tg-width=\"889\" tg-height=\"603\" width=\"100%\" height=\"auto\">Regeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.</p><p><blockquote>再生元制药公司周一表示，在后期试验中使用该药物后的两到八个月内，单剂量其抗体鸡尾酒可将感染 COVID-19 的风险降低 81.6%。</blockquote></p><p> The results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.</p><p><blockquote>美国国立卫生研究院赞助的COVID预防网络单克隆抗体工作负责人迈伦·科恩说，结果表明，抗体疗法REGEN-COV有可能提供对新冠肺炎感染的持久免疫力。</blockquote></p><p> Such immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.</p><p><blockquote>该公司表示，这种免疫力对于免疫功能低下的人和对疫苗没有反应的人尤其重要。</blockquote></p><p> The therapy had previously shown an 81.4% risk reduction during the first month after administration.</p><p><blockquote>该疗法之前在给药后的第一个月内显示风险降低了81.4%。</blockquote></p><p> During the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.</p><p><blockquote>Regeneron 表示，在 8 个月的评估期内，REGEN-COV 组中没有因 COVID-19 住院的病例，但安慰剂组中记录了 6 起此类事件。</blockquote></p><p> The U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.</p><p><blockquote>美国卫生监管机构在7月份扩大了REGEN-COV的授权，使其能够用作接触感染者的人以及在疗养院或监狱等环境中接触感染者的高风险人群的预防性治疗。</blockquote></p><p> It was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.</p><p><blockquote>去年11月，它在美国被授权用于治疗轻度至中度新冠肺炎疾病患者。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"REGN":"再生元制药公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1141245956","content_text":"Regeneron shares rose 2.2% in premarket trading.\nRegeneron Pharmaceuticals Inc said on Monday a single dose of its antibody cocktail reduced the risk of contracting COVID-19 by 81.6% in the two to eight months period following the drug's administration in a late-stage trial.\nThe results showed that antibody therapy, REGEN-COV, has the potential to provide long-lasting immunity from COVID-19 infection, said Myron Cohen, who leads monoclonal antibody efforts for the U.S. National Institutes of Health-sponsored COVID Prevention Network.\nSuch immunity is particularly important for immunocompromised people and those not responding to vaccines, the company said.\nThe therapy had previously shown an 81.4% risk reduction during the first month after administration.\nDuring the 8-month assessment period, there were no hospitalizations for COVID-19 in the REGEN-COV group, but in the placebo group 6 such incidents were recorded, Regeneron said.\nThe U.S. health regulator in July expanded REGEN-COV's authorization to enable its use as a preventive treatment in people exposed to infected individuals, and those at high risk of such exposure in settings such as nursing homes or prisons.\nIt was authorized in the United States last November to treat people with mild-to-moderate COVID-19 disease.","news_type":1,"symbols_score_info":{"REGN":0.9}},"isVote":1,"tweetType":1,"viewCount":2341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":842674025,"gmtCreate":1636175962142,"gmtModify":1636175963148,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like and comment ","listText":"Pls like and comment ","text":"Pls like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/842674025","repostId":"1173813098","repostType":4,"isVote":1,"tweetType":1,"viewCount":2957,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":846055534,"gmtCreate":1636036536957,"gmtModify":1636036936332,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like 👍 ","listText":"Pls like 👍 ","text":"Pls like 👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/846055534","repostId":"1144131531","repostType":4,"repost":{"id":"1144131531","kind":"news","pubTimestamp":1636022596,"share":"https://www.laohu8.com/m/news/1144131531?lang=zh_CN&edition=full","pubTime":"2021-11-04 18:43","market":"us","language":"en","title":"5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1144131531","media":"Motley Fool","summary":"These were some of the fastest-growing large-cap stocks on the planet over a three-year stretch.","content":"<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Be careful: Sales growth alone doesn't always give you the full story about a company.</li> </ul> Since the Great Recession ended in 2009, no group of companies has performed better than growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.</p><p><blockquote><ul><li>要小心：仅仅销售增长并不总是能让你了解一家公司的全部情况。</li></ul>自2009年大衰退结束以来，没有一组公司的表现比成长型股票更好。历史上较低的贷款利率以及美联储坚持使用量化宽松措施来保持低利率，导致大量廉价资本获得。</blockquote></p><p> And it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.</p><p><blockquote>不仅仅是小盘股留下了火热的增长痕迹。根据华尔街的一致销售估计，以下五只大盘股（市值至少为 100 亿美元的公司）到 2023 年的年销售额都有望增长 313%，达到 1,304%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddae655c5dfcf584e1db5b561b7b2051\" tg-width=\"2000\" tg-height=\"1529\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Nio: 447% implied sales growth by 2023</b></p><p><blockquote><b>蔚来：到 2023 年隐含销售额增长 447%</b></blockquote></p><p> Electric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and <b>Nio</b>(NYSE:NIO) is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.</p><p><blockquote>电动汽车 (EV) 制造商应该是十年来发展最快的公司之一，并且<b>蔚来</b>（纽约证券交易所股票代码：NIO）也不例外。继该公司去年销售额达到 25.8 亿美元后，华尔街预测蔚来的评级到 2023 年年销售额将达到约 141 亿美元。</blockquote></p><p> It's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.</p><p><blockquote>众所周知，世界上几乎所有最大的经济体都在采取措施应对气候变化。推动消费者和企业转向电动汽车是减少碳排放最简单的方法之一。蔚来总部位于全球最大的汽车市场中国，据中国汽车工程学会称，到 2035 年，中国每年汽车销量的一半将是电动汽车或混合动力汽车（主要是前者）。</blockquote></p><p> Nio's rapid sales growth is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.</p><p><blockquote>蔚来汽车的销量快速增长是由其创新推动的。该公司每年都会推出一款新的电动汽车，以及其高利润、忠诚度驱动的订阅计划。去年，它推出了电池即服务订阅计划，允许买家升级或更换电池。这项服务还降低了蔚来电动汽车的前期成本。</blockquote></p><p> In exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.</p><p><blockquote>作为放弃近期销售的交换条件，蔚来获得了高利润的每月订阅收入。更重要的是，它让买家对品牌保持忠诚。</blockquote></p><p> Assuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.</p><p><blockquote>假设汽车行业能够克服最近的芯片短缺问题，蔚来扩大产能并在三年内将销售额增加五倍以上应该不会有任何问题。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a0952a9abfc3d69f1c7af0861a2d97b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Snowflake: 401% implied sales growth by 2023</b></p><p><blockquote><b>雪花：到 2023 年隐含销售额增长 401%</b></blockquote></p><p> Although double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company <b>Snowflake</b>(NYSE:SNOW) seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.</p><p><blockquote>尽管两位数的销售额增长在云股票中很常见，但云数据仓库公司<b>雪花</b>（纽约证券交易所股票代码：SNOW）似乎独树一帜。2021财年，Snowflake的销售额约为5.92亿美元。到 2023 日历年结束的 2024 财年，华尔街预计 Snowflake 将产生近 29.7 亿美元的收入。对于那些在家记分的人来说，这是销售额的五倍。</blockquote></p><p> The Snowflake growth story is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.</p><p><blockquote>雪花增长的故事完全是关于竞争优势。例如，Snowflake 没有选择流行的基于订阅的模式，而是根据客户存储的数据量和使用的 Snowflake 计算积分向客户收费。这是一种客户似乎喜欢的更透明的成本方法。</blockquote></p><p> Further, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.</p><p><blockquote>此外，Snowflake的基础设施建立在领先的云基础设施服务提供商之上。这有助于该公司的客户克服竞争云平台之间可能存在的数据共享障碍。</blockquote></p><p> The big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.</p><p><blockquote>最大的问题是 Snowflake 能否支撑其 2022 财年销售额 94 倍的令人鼻血的估值，而盈利能力仍有很长的路要走。为此，我不太确定——但到目前为止，我被证明是错误的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537b181fc66378021049916184ef4425\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Sea Limited: 322% implied sales growth by 2023</b></p><p><blockquote><b>Sea Limited：到 2023 年隐含销售额增长 322%</b></blockquote></p><p> Another large-cap stock with big-time sales-growth expectations is Singapore-based <b>Sea Limited</b>(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.</p><p><blockquote>另一只具有长期销售增长预期的大盘股是新加坡<b>海有限公司</b>（纽约证券交易所代码：SE）。Sea 去年的销售额为 43.8 亿美元。到 2023 年，华尔街预计全年收入约为 185 亿美元。</blockquote></p><p> Sea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate is significantly higher than the industry average.</p><p><blockquote>Sea 成功的众所周知的关键是其多元化的三个高增长领域。首先是数字娱乐，它是唯一一个产生息税折旧摊销前正收益（EBITDA）的公司。截至 6 月底，Sea 季度活跃手机游戏玩家数量为 7.25 亿，其中 12.7% 是付费玩游戏。这一转化率明显高于行业平均水平。</blockquote></p><p></p><p> The company's most exciting segment is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.</p><p><blockquote>该公司最令人兴奋的领域是电子商务平台Shopee，它一直是东南亚下载量最高的购物应用程序，并在巴西实现了快速增长。为了提供有关 Shopee 增长速度的一些背景信息，第二季度交易的商品总价值 (GMV) 为 150 亿美元。与此同时，2018 年全年，Shopee 上的 GMV 仅为 100 亿美元。</blockquote></p><p> Lastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.</p><p><blockquote>最后，Sea 新兴的数字钱包服务领域正在快速增长。该公司拥有接近 3300 万付费移动钱包用户。随着 Sea 专注于众多银行服务不足的地区，这一数字金融服务领域可能会成为未来几年强劲的增长动力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2d05a27ae059e7e27dd31e695de449b2\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>AMC Entertainment: 313% implied sales growth by 2023</b></p><p><blockquote><b>AMC院线：到 2023 年隐含销售额增长 313%</b></blockquote></p><p> Sometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock <b>AMC Entertainment</b>(NYSE:AMC) is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.</p><p><blockquote>有时，仅靠销售增长并不能让投资者了解全貌。例如，电影院股票<b>AMC院线</b>（纽约证券交易所股票代码：AMC）预计销售额将从 2020 年的 12.4 亿美元增长到 2023 年的估计 52.2 亿美元。然而，疫情摧毁了AMC，迫使其许多影院暂时关闭。2023 年 52.2 亿美元的销售额估计仍低于 2019 年（大流行前一年）的 54.7 亿美元销售额。</blockquote></p><p> Whether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.</p><p><blockquote>无论是行业还是公司具体， 似乎没有什么对AMC有利。电影业陷入了19年的下滑，2002年至2019年间，经通胀调整的票房总销售额下降了22%。</blockquote></p><p> Even though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.</p><p><blockquote>尽管AMC已经能够与主要电影公司达成一些独家协议，但这些协议的期限从30天到45天不等。在疫情之前，剧院排他性延长了75到90天。毫无疑问，AMC 已经失去了对电影公司的讨价还价能力，或者流媒体正在蚕食其利润。</blockquote></p><p> As for the company, it's unlikely to be profitable any time before 2024, and the math simply doesn't check out as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.</p><p><blockquote>至于该公司，它不太可能在 2024 年之前的任何时候实现盈利，而且数学根本无法确定它最终将如何偿还 54 亿美元的未偿债务、4.2 亿美元的递延租金和近 49 亿美元的长期租赁负债。由于每周票房总销售额较 2019 年持续下降两位数，毫无疑问 AMC 将继续消耗剩余现金。</blockquote></p><p> Even with \"rapid sales growth,\" some companies should be avoided like the plague.</p><p><blockquote>即使有“销售快速增长”，有些公司也应该像瘟疫一样被避开。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5fc13611f3bbe728494e0ef9d530643\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Moderna: 1,304% implied sales growth by 2023</b></p><p><blockquote><b>Moderna：到 2023 年隐含销售额增长 1,304%</b></blockquote></p><p> The kingpin of sales growth on this list among large-cap companies is biotech-stock <b>Moderna</b>(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.</p><p><blockquote>这份榜单上大盘股销售额增长的主角是生物技术股<b>现代</b>（纳斯达克股票代码：MRNA）。2020年，Moderna的销售额略高于8.03亿美元。分析师预计，到 2023 年，这只热门生物技术股票将产生 112.8 亿美元的收入。这比预期的 1,300% 销售额增长要好。</blockquote></p><p> Chances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.</p><p><blockquote>你可能对Moderna这个名字很熟悉，因为它在冠状病毒疾病2019（新冠肺炎）疫苗方面取得了成功。该公司的疫苗mRNA-1273在去年11月发布的美国临床试验中证明了94%的疫苗效力，并在许多发达市场为成年人接种疫苗方面发挥了关键作用。</blockquote></p><p> The big unknown for Moderna is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.</p><p><blockquote>对于Moderna来说，最大的未知数是mRNA-1273在2021-2022年之后会表现出什么样的腿。一方面，新冠肺炎的变异和疫苗效力随着时间的推移而恶化表明，加强注射可能会成为未来的常规。这将为 Moderna 提供前所未有的经常性收入来源。</blockquote></p><p> On the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.</p><p><blockquote>另一方面，新疫苗即将进入该领域，创新可能会威胁到 Moderna 作为前两名 COVID-19 参与者的地位。例如，如果竞争对手将联合疫苗推向市场（例如，新冠肺炎/流感），这可能会使mRNA-1273成为一个不太诱人的选择。</blockquote></p><p> Considering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.</p><p><blockquote>考虑到 Moderna 1410 亿美元的市值是基于单一疗法，这只股票存在很大风险。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Large-Cap Stocks Expected to Increase Sales 313% to 1,304% by 2023<blockquote>5只大盘股预计到2023年销售额将增长313%至1,304%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-11-04 18:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p><b>Key Points</b></p><p><blockquote><b>要点</b></blockquote></p><p> <ul> <li>Be careful: Sales growth alone doesn't always give you the full story about a company.</li> </ul> Since the Great Recession ended in 2009, no group of companies has performed better than growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.</p><p><blockquote><ul><li>要小心：仅仅销售增长并不总是能让你了解一家公司的全部情况。</li></ul>自2009年大衰退结束以来，没有一组公司的表现比成长型股票更好。历史上较低的贷款利率以及美联储坚持使用量化宽松措施来保持低利率，导致大量廉价资本获得。</blockquote></p><p> And it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.</p><p><blockquote>不仅仅是小盘股留下了火热的增长痕迹。根据华尔街的一致销售估计，以下五只大盘股（市值至少为 100 亿美元的公司）到 2023 年的年销售额都有望增长 313%，达到 1,304%。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ddae655c5dfcf584e1db5b561b7b2051\" tg-width=\"2000\" tg-height=\"1529\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Nio: 447% implied sales growth by 2023</b></p><p><blockquote><b>蔚来：到 2023 年隐含销售额增长 447%</b></blockquote></p><p> Electric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and <b>Nio</b>(NYSE:NIO) is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.</p><p><blockquote>电动汽车 (EV) 制造商应该是十年来发展最快的公司之一，并且<b>蔚来</b>（纽约证券交易所股票代码：NIO）也不例外。继该公司去年销售额达到 25.8 亿美元后，华尔街预测蔚来的评级到 2023 年年销售额将达到约 141 亿美元。</blockquote></p><p> It's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.</p><p><blockquote>众所周知，世界上几乎所有最大的经济体都在采取措施应对气候变化。推动消费者和企业转向电动汽车是减少碳排放最简单的方法之一。蔚来总部位于全球最大的汽车市场中国，据中国汽车工程学会称，到 2035 年，中国每年汽车销量的一半将是电动汽车或混合动力汽车（主要是前者）。</blockquote></p><p> Nio's rapid sales growth is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.</p><p><blockquote>蔚来汽车的销量快速增长是由其创新推动的。该公司每年都会推出一款新的电动汽车，以及其高利润、忠诚度驱动的订阅计划。去年，它推出了电池即服务订阅计划，允许买家升级或更换电池。这项服务还降低了蔚来电动汽车的前期成本。</blockquote></p><p> In exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.</p><p><blockquote>作为放弃近期销售的交换条件，蔚来获得了高利润的每月订阅收入。更重要的是，它让买家对品牌保持忠诚。</blockquote></p><p> Assuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.</p><p><blockquote>假设汽车行业能够克服最近的芯片短缺问题，蔚来扩大产能并在三年内将销售额增加五倍以上应该不会有任何问题。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6a0952a9abfc3d69f1c7af0861a2d97b\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Snowflake: 401% implied sales growth by 2023</b></p><p><blockquote><b>雪花：到 2023 年隐含销售额增长 401%</b></blockquote></p><p> Although double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company <b>Snowflake</b>(NYSE:SNOW) seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.</p><p><blockquote>尽管两位数的销售额增长在云股票中很常见，但云数据仓库公司<b>雪花</b>（纽约证券交易所股票代码：SNOW）似乎独树一帜。2021财年，Snowflake的销售额约为5.92亿美元。到 2023 日历年结束的 2024 财年，华尔街预计 Snowflake 将产生近 29.7 亿美元的收入。对于那些在家记分的人来说，这是销售额的五倍。</blockquote></p><p> The Snowflake growth story is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.</p><p><blockquote>雪花增长的故事完全是关于竞争优势。例如，Snowflake 没有选择流行的基于订阅的模式，而是根据客户存储的数据量和使用的 Snowflake 计算积分向客户收费。这是一种客户似乎喜欢的更透明的成本方法。</blockquote></p><p> Further, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.</p><p><blockquote>此外，Snowflake的基础设施建立在领先的云基础设施服务提供商之上。这有助于该公司的客户克服竞争云平台之间可能存在的数据共享障碍。</blockquote></p><p> The big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.</p><p><blockquote>最大的问题是 Snowflake 能否支撑其 2022 财年销售额 94 倍的令人鼻血的估值，而盈利能力仍有很长的路要走。为此，我不太确定——但到目前为止，我被证明是错误的。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/537b181fc66378021049916184ef4425\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Sea Limited: 322% implied sales growth by 2023</b></p><p><blockquote><b>Sea Limited：到 2023 年隐含销售额增长 322%</b></blockquote></p><p> Another large-cap stock with big-time sales-growth expectations is Singapore-based <b>Sea Limited</b>(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.</p><p><blockquote>另一只具有长期销售增长预期的大盘股是新加坡<b>海有限公司</b>（纽约证券交易所代码：SE）。Sea 去年的销售额为 43.8 亿美元。到 2023 年，华尔街预计全年收入约为 185 亿美元。</blockquote></p><p> Sea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate is significantly higher than the industry average.</p><p><blockquote>Sea 成功的众所周知的关键是其多元化的三个高增长领域。首先是数字娱乐，它是唯一一个产生息税折旧摊销前正收益（EBITDA）的公司。截至 6 月底，Sea 季度活跃手机游戏玩家数量为 7.25 亿，其中 12.7% 是付费玩游戏。这一转化率明显高于行业平均水平。</blockquote></p><p></p><p> The company's most exciting segment is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.</p><p><blockquote>该公司最令人兴奋的领域是电子商务平台Shopee，它一直是东南亚下载量最高的购物应用程序，并在巴西实现了快速增长。为了提供有关 Shopee 增长速度的一些背景信息，第二季度交易的商品总价值 (GMV) 为 150 亿美元。与此同时，2018 年全年，Shopee 上的 GMV 仅为 100 亿美元。</blockquote></p><p> Lastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.</p><p><blockquote>最后，Sea 新兴的数字钱包服务领域正在快速增长。该公司拥有接近 3300 万付费移动钱包用户。随着 Sea 专注于众多银行服务不足的地区，这一数字金融服务领域可能会成为未来几年强劲的增长动力。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2d05a27ae059e7e27dd31e695de449b2\" tg-width=\"2000\" tg-height=\"1333\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>AMC Entertainment: 313% implied sales growth by 2023</b></p><p><blockquote><b>AMC院线：到 2023 年隐含销售额增长 313%</b></blockquote></p><p> Sometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock <b>AMC Entertainment</b>(NYSE:AMC) is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.</p><p><blockquote>有时，仅靠销售增长并不能让投资者了解全貌。例如，电影院股票<b>AMC院线</b>（纽约证券交易所股票代码：AMC）预计销售额将从 2020 年的 12.4 亿美元增长到 2023 年的估计 52.2 亿美元。然而，疫情摧毁了AMC，迫使其许多影院暂时关闭。2023 年 52.2 亿美元的销售额估计仍低于 2019 年（大流行前一年）的 54.7 亿美元销售额。</blockquote></p><p> Whether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.</p><p><blockquote>无论是行业还是公司具体， 似乎没有什么对AMC有利。电影业陷入了19年的下滑，2002年至2019年间，经通胀调整的票房总销售额下降了22%。</blockquote></p><p> Even though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.</p><p><blockquote>尽管AMC已经能够与主要电影公司达成一些独家协议，但这些协议的期限从30天到45天不等。在疫情之前，剧院排他性延长了75到90天。毫无疑问，AMC 已经失去了对电影公司的讨价还价能力，或者流媒体正在蚕食其利润。</blockquote></p><p> As for the company, it's unlikely to be profitable any time before 2024, and the math simply doesn't check out as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.</p><p><blockquote>至于该公司，它不太可能在 2024 年之前的任何时候实现盈利，而且数学根本无法确定它最终将如何偿还 54 亿美元的未偿债务、4.2 亿美元的递延租金和近 49 亿美元的长期租赁负债。由于每周票房总销售额较 2019 年持续下降两位数，毫无疑问 AMC 将继续消耗剩余现金。</blockquote></p><p> Even with \"rapid sales growth,\" some companies should be avoided like the plague.</p><p><blockquote>即使有“销售快速增长”，有些公司也应该像瘟疫一样被避开。</blockquote></p><p> <p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b5fc13611f3bbe728494e0ef9d530643\" tg-width=\"2000\" tg-height=\"1334\" width=\"100%\" height=\"auto\"><span>IMAGE SOURCE: GETTY IMAGES.</span></p><p><blockquote><p class=\"t-img-caption\"><span>图片来源：盖蒂图片社。</span></p></blockquote></p><p> <b>Moderna: 1,304% implied sales growth by 2023</b></p><p><blockquote><b>Moderna：到 2023 年隐含销售额增长 1,304%</b></blockquote></p><p> The kingpin of sales growth on this list among large-cap companies is biotech-stock <b>Moderna</b>(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.</p><p><blockquote>这份榜单上大盘股销售额增长的主角是生物技术股<b>现代</b>（纳斯达克股票代码：MRNA）。2020年，Moderna的销售额略高于8.03亿美元。分析师预计，到 2023 年，这只热门生物技术股票将产生 112.8 亿美元的收入。这比预期的 1,300% 销售额增长要好。</blockquote></p><p> Chances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.</p><p><blockquote>你可能对Moderna这个名字很熟悉，因为它在冠状病毒疾病2019（新冠肺炎）疫苗方面取得了成功。该公司的疫苗mRNA-1273在去年11月发布的美国临床试验中证明了94%的疫苗效力，并在许多发达市场为成年人接种疫苗方面发挥了关键作用。</blockquote></p><p> The big unknown for Moderna is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.</p><p><blockquote>对于Moderna来说，最大的未知数是mRNA-1273在2021-2022年之后会表现出什么样的腿。一方面，新冠肺炎的变异和疫苗效力随着时间的推移而恶化表明，加强注射可能会成为未来的常规。这将为 Moderna 提供前所未有的经常性收入来源。</blockquote></p><p> On the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.</p><p><blockquote>另一方面，新疫苗即将进入该领域，创新可能会威胁到 Moderna 作为前两名 COVID-19 参与者的地位。例如，如果竞争对手将联合疫苗推向市场（例如，新冠肺炎/流感），这可能会使mRNA-1273成为一个不太诱人的选择。</blockquote></p><p> Considering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.</p><p><blockquote>考虑到 Moderna 1410 亿美元的市值是基于单一疗法，这只股票存在很大风险。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","SNOW":"Snowflake","SE":"Sea Ltd","NIO":"蔚来","AMC":"AMC院线"},"source_url":"https://www.fool.com/investing/2021/11/04/5-large-cap-stocks-increase-sales-313-to-1304/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1144131531","content_text":"Key Points\n\nBe careful: Sales growth alone doesn't always give you the full story about a company.\n\nSince the Great Recession ended in 2009, no group of companies has performed better than growth stocks. Historically low lending rates and the Federal Reserve's insistence on using quantitative-easing measures to keep rates low has led to abundant access to cheap capital.\nAnd it's not just small-cap stocks that are leaving a fiery trail of growth in their wake. According to consensus sales estimates from Wall Street, the following five large-cap stocks(companies with market caps of at least $10 billion) are all on pace to grow their annual sales by 313% to as much as 1,304% by 2023.\nIMAGE SOURCE: GETTY IMAGES.\nNio: 447% implied sales growth by 2023\nElectric-vehicle(EV) manufacturers should be some of the fastest-growing companies of the decade, and Nio(NYSE:NIO) is no exception. After the company produced $2.58 billion in sales last year, Wall Street's forecast calls for Nio to drive home roughly $14.1 billion in annual sales by 2023.\nIt's no secret that virtually all of the largest economies in the world are taking steps to fight climate change. Pushing consumers and enterprises to shift to EVs is one of the easiest ways to reduce carbon emissions. Nio is headquartered in the largest auto market in the world, China, which should see half of its annual vehicle sales be EVs or hybrids (mostly the former) by 2035, according to the Society of Automotive Engineers of China.\nNio's rapid sales growth is being driven by its innovation. The company is introducing a new EV each year -- and its high-margin, loyalty-driven subscription program. Last year, it introduced a battery-as-a-service subscription program that'll allow buyers to upgrade or replace their batteries. This service also reduces the upfront cost of Nio's EVs.\nIn exchange for giving up near-term sales, Nio is receiving high-margin monthly subscription revenue. More importantly, it's keeping buyers loyal to the brand.\nAssuming the auto industry can overcome recent chip shortages, Nio shouldn't have any trouble expanding its capacity and more than quintupling its sales in three years.\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: 401% implied sales growth by 2023\nAlthough double-digit sales growth is commonplace among cloud stocks, cloud data-warehousing company Snowflake(NYSE:SNOW) seems to be in a league of its own. In fiscal 2021, Snowflake brought in about $592 million in sales. By fiscal 2024, which ends in calendar year 2023, Wall Street is looking for Snowflake to generate almost $2.97 billion in revenue. That's a quintupling in sales, for those of you keeping score at home.\nThe Snowflake growth story is all about competitive advantages. For example, instead of opting for the popular subscription-based model, Snowflake charges its customers based on how much data they store and how many Snowflake Compute Credits used. This is a more transparent cost approach that its customers seem to like.\nFurther, Snowflake's infrastructure is built atop the leading cloud-infrastructure service providers. This helps the company's clients work around data-sharing barriers that might otherwise exist between competing cloud platforms.\nThe big question is whether Snowflake can support its nosebleed valuation of 94 times projected fiscal 2022 sales, with profitability still a long way off. To that end, I'm not so sure -- but Ihave been proven wrong, thus far.\nIMAGE SOURCE: GETTY IMAGES.\nSea Limited: 322% implied sales growth by 2023\nAnother large-cap stock with big-time sales-growth expectations is Singapore-based Sea Limited(NYSE:SE). Sea reported $4.38 billion in sales last year. Come 2023, Wall Street is expecting roughly $18.5 billion in full-year revenue.\nSea's not-so-secret key to success is its diversified trio of high-growth segments. First, there's digital entertainment, which is the only one generating positive earnings before interest, taxes, depreciation, and amortization (EBITDA). Sea ended June with 725 million quarterly active mobile gamers, 12.7% of which were paying to play. This conversion rate is significantly higher than the industry average.\nThe company's most exciting segment is e-commerce platform Shopee, which has consistently been the most-downloaded shopping app in Southeastern Asia and has seen rapid growth in Brazil. To offer some context as to how quickly Shopee is growing, the gross merchandise value (GMV) transacted in the second quarter was $15 billion. Meanwhile, only $10 billion in GMV was registered on Shopee in all of 2018.\nLastly, Sea's nascent digital-wallet services segment is growing rapidly. The company is nearing 33 million paying mobile-wallet users. With Sea focusing on numerous underbanked regions, this digital financial-services segment could be a sneaky strong growth driver for years to come.\nIMAGE SOURCE: GETTY IMAGES.\nAMC Entertainment: 313% implied sales growth by 2023\nSometimes, sales growth alone doesn't give investors the full picture. For instance,movie-theater stock AMC Entertainment(NYSE:AMC) is slated to grow its sales from $1.24 billion in 2020 to an estimated $5.22 billion by 2023. However, the pandemic ravaged AMC and forced many of its theaters to temporarily close. This $5.22 billion estimate for 2023 still represents a decline from the $5.47 billion in sales recorded in 2019, the year prior to the pandemic.\nWhether it's industry or company specific,nothing seems to be working in AMC's favor. The movie-theater industry has been mired in a 19-year decline, with inflation-adjusted box-office gross sales falling 22% between 2002 and 2019.\nEven though AMC has been able to secure some exclusivity agreements with major studios, these agreements range from 30 to 45 days. Prior to the pandemic, theatrical exclusivity extended 75 to 90 days. There's no question that AMC has lost its bargaining power to studios, or that streaming is eating into its margins.\nAs for the company, it's unlikely to be profitable any time before 2024, and the math simply doesn't check out as to how it'll eventually pay back its $5.4 billion in outstanding debt, $420 million in deferred rent, and nearly $4.9 billion in long-term lease liabilities. With weekly box-office gross sales consistently down double digits from 2019, there's little doubt AMC will continue to burn through its remaining cash.\nEven with \"rapid sales growth,\" some companies should be avoided like the plague.\nIMAGE SOURCE: GETTY IMAGES.\nModerna: 1,304% implied sales growth by 2023\nThe kingpin of sales growth on this list among large-cap companies is biotech-stock Moderna(NASDAQ:MRNA). In 2020, Moderna posted a little over $803 million in sales. By 2023, analysts expect this hot biotech stock to yield $11.28 billion in revenue. That's a better than 1,300% expected sales increase.\nChances are you're familiar with the Moderna name because of its success on the coronavirus disease 2019 (COVID-19) vaccine front. The company's vaccine, mRNA-1273, demonstrated 94% vaccine efficacy in a U.S. clinical trial released last November and has played a key role in inoculating adults in numerous developed markets.\nThe big unknown for Moderna is what sort of legs mRNA-1273 will exhibit beyond 2021-2022. On one hand, variants of COVID-19 and the deterioration of vaccine efficacy over time suggests that booster shots may become a routine moving forward. This would offer Moderna a recurring revenue stream that it's never had before.\nOn the other hand, new vaccines are set to enter the space, and innovation could threaten Moderna's grip as a top-two COVID-19 player. For example, if competitors bring combination vaccines to market (e.g., COVID-19/influenza), it could make mRNA-1273 a less-tantalizing option.\nConsidering that Moderna's $141 billion market cap is based on a single therapeutic, there's a lot of risk built into this stock.","news_type":1,"symbols_score_info":{"SNOW":0.9,"AMC":0.9,"NIO":0.9,"SE":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3955,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":848062168,"gmtCreate":1635948641869,"gmtModify":1635948740884,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/848062168","repostId":"1100947774","repostType":2,"isVote":1,"tweetType":1,"viewCount":3280,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":843537042,"gmtCreate":1635840741218,"gmtModify":1635840741544,"author":{"id":"3574927270640767","authorId":"3574927270640767","name":"junior_daddy","avatar":"https://static.tigerbbs.com/15d3e810c8746da472a70549c212570d","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3574927270640767","idStr":"3574927270640767"},"themes":[],"title":"","htmlText":"Pls like ","listText":"Pls like ","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843537042","repostId":"1129449747","repostType":4,"repost":{"id":"1129449747","kind":"news","pubTimestamp":1635839802,"share":"https://www.laohu8.com/m/news/1129449747?lang=zh_CN&edition=full","pubTime":"2021-11-02 15:56","market":"us","language":"en","title":"Cathie Wood Stands to Make a Lot of Money From Skillz Stock<blockquote>凯西·伍德(Cathie Wood)将从Skillz股票中赚很多钱</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1129449747","media":"InvestorPlace","summary":"SKLZ stock, while volatile, has the potential to be a 10-bagger","content":"<p><div> The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming ...</p><p><blockquote><div>Ark Innovation ETF(NYSEARCA：ARKK)于10月21日购买了210万股Skillz(NYSE：SKLZ)股票。据24/7 Wall St.报道，SKLZ股票的购买使ETF持有的电子竞技游戏总量...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">网页连接</a></blockquote></p><p></p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cathie Wood Stands to Make a Lot of Money From Skillz Stock<blockquote>凯西·伍德(Cathie Wood)将从Skillz股票中赚很多钱</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCathie Wood Stands to Make a Lot of Money From Skillz Stock<blockquote>凯西·伍德(Cathie Wood)将从Skillz股票中赚很多钱</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">InvestorPlace</strong><span class=\"h-time small\">2021-11-02 15:56</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming ...</p><p><blockquote><div>Ark Innovation ETF(NYSEARCA：ARKK)于10月21日购买了210万股Skillz(NYSE：SKLZ)股票。据24/7 Wall St.报道，SKLZ股票的购买使ETF持有的电子竞技游戏总量...</div></blockquote></p><p> <a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">网页链接</a> </div> </p><p><blockquote><a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/\">InvestorPlace</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/11/cathie-wood-stands-to-make-a-lot-of-money-from-skillz-sklz-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1129449747","content_text":"The Ark Innovation ETF(NYSEARCA:ARKK) bought2.1 million shares of Skillz(NYSE:SKLZ) on Oct. 21., according to 24/7 Wall St., the SKLZ stock buy brings the ETF’s total holdings of the esports gaming platform company to 13.3 million shares.\nAlthough the SKILLZ position is only good for 0.70% of the ETF’s $19.4 billion in total assets, it’s got a shot at becoming one of the star portfolio manager’s biggest successes.\nWell, maybe not Tesla(NASDAQ:TSLA) big, but significant all the same. For example, if Skillz stock miraculously reverted to its all-time high of $46.30, which it hit in February, the ETF’s Skillz shares would be worth $617.2 million and a weighting of 3.18%. That’s good for 11th position. Currently, it’s 34th.\nSince the share purchase, SKLZ stock has gained almost 17% through the second-last trading day in October. It’s on a roll.\nSKLZ Stock: Where to From Here?\nThere is no doubt the short-sellers are battling it out with the Reddit crowd over the ultimate direction of Skillz stock. More than 555 million shares,or 23% of its total, are sold short.\nA short squeeze seems possible in the near term, but the reality, like many stocks, is that neither side appears ready to take the bull by the horns.\nIn the interim, Wood keeps building her position in the company.\nOver at the ARK Next Generation Internet ETF(NYSEARCA:ARKW), the fund holds 7.0 million shares of Skillz, good for 22nd position in ARKW. So, put those two positions together, move up to $46.30 in the blink of an eye, and Ark Investment Management is sitting on a $1 billion investment.\nAnd it could get even better than that.\nThe portfolio manager has been selling little bits of Tesla as it’s moved over $1,000 in recent weeks. On Oct. 21 and 22, she sold more than 126,000 shares for proceeds of $114 million. Then on Oct. 25, she sold another 22,598 shares of Tesla.\nThose proceeds have to go into other stocks at some point.\nAnother Successful Quarter of Sales Growth\nSkillz has been able to string together 22 consecutive quarters of sales growth — profits, or should I say losses, are another story altogether — and looks likely to ring in a 23rd consecutive quarter of strong sales growth when it reports earnings in early November.\nThe analyst estimate for Q3 2021 is $102.3 million. The company’s full-year guidance is for $375 million. That doesn’t even include its acquisition of Aarki.\nIn July, I suggested that Aarki insiders should hang on to the four million shares of SKLZ stock they got as part of the sale to Skillz.\n“Between Wood’s ownership, the fact that Skillz came public through a Jeff Sagansky and Harry Sloan SPAC, and the company participates in mobile gaming, one of the hottest industries around, I think the risk-reward proposition is excellent between $15 and $20,” I wrote on July 14.\n“If you buy at current prices, be prepared for a lot of volatility. I would not be surprised if it tests $15 on the downside again soon. If you do buy now, I’d keep some cash on the sidelines so you can buy some more at $15 or less.”\nI also said that adding Aarki to the mix should help Skillz keep generating more revenue from users, commonly referred to as ARPU, or average revenue per user.\nIn the second quarter, it reported an ARPU of $12.46. That was 20.4% higher than the first quarter of 2021. So if it can keep moving the needle higher, you can be sure the profits will start to roll.\nInvestorPlace’s Alex Sirois believes that investors should wait to buy until after the third-quarter results are released before making a move.\n“Losses nearly quadrupled in Q2 on a year-over-year basis, rising to $79.6 million from $20.2 million a year ago. It was a similar story in the first quarter, with the company’s net loss widening to $53.6 million from $15.5 million in the first quarter of 2021,” Sirois stated on Oct. 28.\n“So, although analysts are predicting strong revenue growth, I wouldn’t jump into SKLZ stock until the company proves it can control its losses.”\nWhile I get where my colleague is coming from, the company has plenty of cash ($692.8 million) to get it through the rest of this fiscal year and all of fiscal 2022. So I would be squarely fixed on top-line growth and ARPU.\nIf these two numbers grew sequentially and year-over-year by double digits, all’s good with the company. Worrying about losses at this point is how investors miss out and quality growth stories like Skillz.\nAnd, besides, as my colleague says, there’s a lot of good things happening in its product development at the moment. So avoid the noise and focus on what matters for SKLZ stock in the near term.\nWhile Cathie Wood has been both a buyer and seller of SKLZ stock, ultimately, I believe she’ll make out like a bandit.","news_type":1,"symbols_score_info":{"SKLZ":0.9}},"isVote":1,"tweetType":1,"viewCount":3716,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}